Corpus ID: 235390527

In silico Prediction of Mozenavir as potential drug for SARS-CoV-2 infection via Binding Multiple Drug Targets

  title={In silico Prediction of Mozenavir as potential drug for SARS-CoV-2 infection via Binding Multiple Drug Targets},
  author={Estari Mamidalaa and Rakesh Davella and Swapna Gurrapu and Munipally Praveen Kumar and Abhiav},
Since the epidemic began in November 2019, no viable medicine against SARS-CoV-2 has been discovered. The typical medication discovery strategy requires several years of rigorous research and development as well as a significant financial commitment, which is not feasible in the face of the current epidemic. Through molecular docking and dynamic simulation studies, we used the FDA-approved drug mezonavir against the most important viral targets, including spike (S) glycoprotein, Transmembrane… Expand
1 Citations
Structural deformability induced in proteins of potential interest associated with COVID-19 by binding of homologues present in ivermectin: Comparative study based in elastic networks models
The COVID-19 pandemic has accelerated the study of the potential of multi-target drugs (MTDs). The mixture of homologues called ivermectin (avermectin-B1a + avermectin-B1b) has been shown to be aExpand


An In Silico Approach for Identification of Inhibitors as a Potential Therapeutics Targeting SARS-Cov-2 Protease
SARS-CoV-2 caused COVID-19 which is pandemic and is a global health emergency. Protease is the drug target for corona viruses and this enzyme processes the production of polyproteins from the viralExpand
Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase
Although the current study lacks experimental validation, the structural information obtained from this computational study has paved way for the design of targeted inhibitors to combat COVID-19 outbreak. Expand
In Silico Identification of Clinically Approved Medicines Against the main Protease of Sars-Cov-2 – A Causative Agent of Covid-19
The potential inhibitory activity of some FDA approved drugs against SARS-CoV-2 main protease is reported by molecular docking study to investigate their binding affinity in protease active site. Expand
Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms
Nine antiviral secondary metabolites from fungi were docked onto five SARS-CoV2 enzymes involved in viral attachment, replication, post-translational modification, and host immunity evasion infection mechanisms followed by molecular dynamics simulation and in silico ADMET prediction. Expand
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
  • Zhenming Jin, Xiaoyu Du, +28 authors Haitao Yang
  • Medicine
  • Nature
  • 2020
A programme of structure-assisted drug design and high-throughput screening identifies six compounds that inhibit the main protease of SARS-CoV-2, demonstrating the ability of this strategy to isolate drug leads with clinical potential. Expand
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry. Expand
Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
A promising NA candidate is mapped to the nucleoside active site of SARS-CoV RdRp and ExoN proteins, identifying the residues important for nucleotide recognition, discrimination, and excision, and Interestingly, GS-441524 addresses both enzyme active sites in a manner consistent with significant incorporation, delayed chain termination, and altered excision due to the ribose 1'-CN group, which may account for the increased antiviral effect. Expand
Coronavirus membrane fusion mechanism offers a potential target for antiviral development
The role of the CoV spike protein in mediating fusion of the viral and host cell membranes is reviewed, summarizing the results of research on SARS- CoV, MERS-CoV, and recent peer-reviewed studies of SARS -CoV-2, and it is suggested that the fusion mechanism be investigated as a potential antiviral target. Expand
Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?
The advantage of targeting one of the non-structural proteins, helicase (nsp13), over other SARS-CoV-2 proteins is highlighted, and research on helicase inhibitors as potential COVID-19 therapy is called for. Expand
A facile Q-RT-PCR assay for monitoring SARS-CoV-2 growth in cell culture
A facile Q-RT-PCR assay that bypasses viral RNA extraction steps and can monitor SARS-CoV-2 replication kinetics from a small amount of cell culture supernatants is developed and is as accurate and sensitive as existing methods. Expand